黛力新对女性更年期功能性消化不良的临床效果

Clinical effect of deanxit on female menopause functional dyspepsia

目的探讨黛力新在女性更年期功能性消化不良治疗中的临床应用效果。方法随机数表法抽取医院接受莫沙必利联合雷贝拉唑治疗的更年期功能性消化不良女性患者46例（对照组），接受黛力新联合莫沙必利、雷贝拉唑治疗的更年期功能性消化不良女性患者46例（观察组），比较两组患者治疗前后的汉密尔顿焦虑量表（HAMA）评分、汉密尔顿抑郁量表（HAMD）评分、不良反应发生情况及治疗效果。结果两组患者治疗前HAMA评分及HAMD评分比较差异未见统计学意义（P〉0.05）。观察组治疗后HAMA评分（5.27±1.42）分及HAMD评分（5.69±1.38）分均优于对照组治疗后HAMA评分（15.23±2.33）分及HAMD评分（13.74±3.09）分；在治疗过程中，观察组不良反应发生率（2.17%）明显低于对照组不良反应发生率（13.04%）；观察组总有效率（97.83%）明显高于对照组总有效率（84.78%）；差异均有统计学意义（P〈0.05）。结论黛力新在女性更年期功能性消化不良治疗中的临床应用效果显著，能够有效缓解并消除患者的疾病症状，减少不良反应发生情况并提高治疗总有效率，对更年期功能性消化不良女性患者的身体健康具有重要保障，值得临床推广应用。

ObjectiveTo investigate the clinical effect of deanxit on treatment of functional dyspepsia in women.MethodsForty-six patients with menopausal functional dyspepsia treated with mosapride combined with rabeprazole were enrolled （control group） by random number table method, and 46 patients with functional dyspepsia treated with deanxit, mosaride and rabeprazole were enrolled as the observation group. Hamiltonian anxiety scale （HAMA） score, and Hamilton depression （HAMD） score and adverse reactions were compared between the two groups before and after treatment.ResultsThere was no significant difference in HAMA score or HAMD score between the two groups before treatment （P〉0.05）. After treatment, the HAMA score （5.27±1.42） and the HAMD score （5.69±1.38） were significantly higher in the observation group than those in the control group （15.23±2.33） and the HAMD score （13.74±3.09）. During the course of treatment, the incidence of adverse reactions in the observation group （2.17%） was significantly lower than that in the control group （13.04%）. The total effective rate （97.83%） in the observation group was significantly higher than that in the control group （84.78%）, the differences were significant（P〈0.05）.ConclusionsDeanxit has significant clinical effect on female menopausal functional dyspepsia, which can effectively relieve and eliminate the symptoms of the patients, reduce the incidence of adverse reactions and improve the total effective rate of treatment. Deanxit has important guarantee for the physical health of patients with menopausal functional dyspepsia, so it is worthy of clinical application.